152 related articles for article (PubMed ID: 21423022)
1. CD4+ lymphocyte-based immunologic outcomes of perinatally HIV-infected children during antiretroviral therapy interruption.
Siberry GK; Patel K; Van Dyke RB; Hazra R; Burchett SK; Spector SA; Paul ME; Read JS; Wiznia A; Seage GR;
J Acquir Immune Defic Syndr; 2011 Jul; 57(3):223-9. PubMed ID: 21423022
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.
Van Dyke RB; Patel K; Siberry GK; Burchett SK; Spector SA; Chernoff MC; Read JS; Mofenson LM; Seage GR;
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):165-73. PubMed ID: 21407086
[TBL] [Abstract][Full Text] [Related]
3. CD4 recovery following antiretroviral treatment interruptions in children and adolescents with HIV infection in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
HIV Med; 2019 Aug; 20(7):456-472. PubMed ID: 31099155
[TBL] [Abstract][Full Text] [Related]
4. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
Fairlie L; Karalius B; Patel K; van Dyke RB; Hazra R; Hernán MA; Siberry GK; Seage GR; Agwu A; Wiznia A;
AIDS; 2015 Oct; 29(16):2109-19. PubMed ID: 26182197
[TBL] [Abstract][Full Text] [Related]
5. Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV.
Sudjaritruk T; Boettiger DC; Nguyen LV; Mohamed TJ; Wati DK; Bunupuradah T; Hansudewechakul R; Ly PS; Lumbiganon P; Nallusamy RA; Fong MS; Chokephaibulkit K; Nik Yusoff NK; Truong KH; Do VC; Sohn AH; Sirisanthana V;
J Int AIDS Soc; 2019 Jun; 22(6):e25312. PubMed ID: 31179641
[TBL] [Abstract][Full Text] [Related]
6. Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA.
Rakhmanina N; Lam KS; Hern J; Young HA; Walters A; Castel AD
J Int AIDS Soc; 2016; 19(1):20936. PubMed ID: 27797320
[TBL] [Abstract][Full Text] [Related]
7. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
[TBL] [Abstract][Full Text] [Related]
8. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.
Judd A; Doerholt K; Tookey PA; Sharland M; Riordan A; Menson E; Novelli V; Lyall EG; Masters J; Tudor-Williams G; Duong T; Gibb DM; ;
Clin Infect Dis; 2007 Oct; 45(7):918-24. PubMed ID: 17806062
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).
Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J
Clin Infect Dis; 2010 Jul; 51(2):214-24. PubMed ID: 20536367
[TBL] [Abstract][Full Text] [Related]
11. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
12. Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study.
Mossoro-Kpinde CD; Gody JC; Mboumba Bouassa RS; Moussa S; Jenabian MA; Péré H; Charpentier C; Matta M; Longo JD; Grésenguet G; Djoba Siawaya JF; Bélec L
Medicine (Baltimore); 2020 May; 99(21):e19978. PubMed ID: 32481261
[TBL] [Abstract][Full Text] [Related]
13. The reliability of point-of-care CD4 testing in identifying HIV-infected pregnant women eligible for antiretroviral therapy.
Mnyani CN; McIntyre JA; Myer L
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):260-4. PubMed ID: 22487589
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
[TBL] [Abstract][Full Text] [Related]
15. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States.
Griner R; Williams PL; Read JS; Seage GR; Crain M; Yogev R; Hazra R; Rich K;
AIDS Patient Care STDS; 2011 Jul; 25(7):385-94. PubMed ID: 21992592
[TBL] [Abstract][Full Text] [Related]
16. Time to Viral Suppression in Perinatally HIV-Infected Infants Depends on the Viral Load and CD4 T-Cell Percentage at the Start of Treatment.
Schröter J; Anelone AJN; Yates AJ; de Boer RJ;
J Acquir Immune Defic Syndr; 2020 Apr; 83(5):522-529. PubMed ID: 31917752
[TBL] [Abstract][Full Text] [Related]
17. Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.
Kesho Bora Study Group
J Acquir Immune Defic Syndr; 2010 Aug; 54(5):533-41. PubMed ID: 20543706
[TBL] [Abstract][Full Text] [Related]
18. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
19. Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.
Bhargav H; Huilgol V; Metri K; Sundell IB; Tripathi S; Ramagouda N; Jadhav M; Raghuram N; Ramarao NH; Koka PS
J Stem Cells; 2012; 7(3):127-53. PubMed ID: 23619381
[TBL] [Abstract][Full Text] [Related]
20. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium.
Desmonde S; Neilan AM; Musick B; Patten G; Chokephaibulkit K; Edmonds A; Duda SN; Malateste K; Wools-Kaloustian K; Ciaranello AL; Davies MA; Leroy V;
J Int AIDS Soc; 2020 Oct; 23(10):e25617. PubMed ID: 33034417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
